Patient Support for VELETRI® (epoprostenol)

Once you and your healthcare provider have decided that VELETRI® is right for you, Janssen CarePath will help you find the resources you may need to get started and stay on track. We will give you information on your insurance coverage, potential out-of-pocket costs, and treatment support, and identify options that may help make your treatment more affordable.

Connecting with financial assistance programs

At Janssen, we don't want cost to get in the way of treatment you need. We can help you explore options to lower your out-of-pocket cost for VELETRI®. No matter what type of insurance you have – or even if you don't have insurance – Janssen CarePath can help explain your medication insurance coverage and potential out-of-pocket costs and help find programs that may help you pay for VELETRI®.

Janssen CarePath can provide information about other resources that may be able to help with your out-of-pocket medication costs for VELETRI®.

Call a Janssen CarePath Care Coordinator at 866-228-3546 for more information about affordability programs and independent foundations that may have funding available.

Independent co-pay assistance foundations have their own rules for eligibility. We cannot guarantee a foundation will help you. We only can refer you to a foundation that supports your disease state. This information is provided as a resource for you. We do not endorse any particular foundation.

Additional support resources

The following independent patient advocacy organizations offer education and support to patients. Visit their websites for PAH information, news, and ideas about how to get involved with the PAH community.

The Pulmonary Hypertension Association is dedicated to increasing awareness and advocacy by providing information about PAH to both physicians and patients.

The Scleroderma Foundation offers a site for scleroderma patients, caregivers, and family members—dedicated to support, education, and research.

Contact a Care Coordinator with questions at 866-228-3546, Monday-Friday, 8 AM to 8 PM ET.

see more

What is VELETRI® (epoprostenol) for Injection?

VELETRI® is a prescription medicine that is given intravenously (in a vein). It is used to treat adults with certain kinds of severe pulmonary arterial hypertension (PAH) (WHO Group 1), a condition in which blood pressure is too high in the blood vessels between the heart and the lungs. VELETRI® may improve your ability to exercise as measured by how far you can walk in 6 minutes (6-minute walk test).

Studies showing VELETRI® is effective included mainly patients with NYHA Functional Class III-IV PAH. In these patients, PAH was caused by unidentified or hereditary factors or connective tissue disease.

IMPORTANT SAFETY INFORMATION

Who should not take VELETRI®?

VELETRI® should not be used if you have heart failure due to severe left heart disease, if you develop fluid in the lungs (pulmonary edema) when starting therapy, or if you are allergic to epoprostenol.

Some medications may interact with VELETRI®. Please talk to your doctor about all of your medications.

What is the most important information I should know about VELETRI®?

It is important to use VELETRI® as directed by your doctor. VELETRI® should be used only with Sterile Water for Injection, USP, or Sodium Chloride 0.9% Injection, USP. Do not mix VELETRI® with other intravenous medications. Each vial is for single use only; discard any unused medication. Use at room temperature (77°F/25°C). Do not expose VELETRI® to direct sunlight.

back to top

What is VELETRI® (epoprostenol) for Injection?

VELETRI® is a prescription medicine that is given intravenously (in a vein). It is used to treat adults with certain kinds of severe pulmonary arterial hypertension (PAH) (WHO Group 1), a condition in which blood pressure is too high in the blood vessels between the heart and the lungs. VELETRI® may improve your ability to exercise as measured by how far you can walk in 6 minutes (6-minute walk test).

Studies showing VELETRI® is effective included mainly patients with NYHA Functional Class III-IV PAH. In these patients, PAH was caused by unidentified or hereditary factors or connective tissue disease.

IMPORTANT SAFETY INFORMATION

Who should not take VELETRI®?

VELETRI® should not be used if you have heart failure due to severe left heart disease, if you develop fluid in the lungs (pulmonary edema) when starting therapy, or if you are allergic to epoprostenol.

Some medications may interact with VELETRI®. Please talk to your doctor about all of your medications.

What is the most important information I should know about VELETRI®?

It is important to use VELETRI® as directed by your doctor. VELETRI® should be used only with Sterile Water for Injection, USP, or Sodium Chloride 0.9% Injection, USP. Do not mix VELETRI® with other intravenous medications. Each vial is for single use only; discard any unused medication. Use at room temperature (77°F/25°C). Do not expose VELETRI® to direct sunlight.

When you take epoprostenol for the first time, you must be in a setting (hospital or clinic) where you can be monitored for any serious side effects or in case of emergency. Your blood pressure and heart rate should also be monitored with any dose changes. If you are taking VELETRI®, your doctor may prescribe another kind of medicine used to prevent blood clots. It is the use of these medications concomitantly (in combination) with VELETRI® that may potentially cause an increase in the risk of bleeding.

Sudden and dramatic changes in dose may lead to unstable blood pressure, a return of pulmonary hypertension symptoms, or fatal low blood pressure (hypotension). Do not stop using VELETRI® without first talking to your doctor.

To reduce the risk of infection in the bloodstream, it is important to know how to properly care for the catheter and infusion pump.

What are the possible side effects of VELETRI®?

You may have side effects at the start of treatment or with dose increases. The most common side effects seen in at least 1% of patients were:

  • flushing
  • headache
  • nausea/vomiting
  • low blood pressure
  • anxiety/nervousness
  • chest pain
  • dizziness
  • slow heartbeat
  • abdominal pain
  • pain in the muscles and/or ligaments and bones
  • shortness of breath
  • back pain
  • sweating
  • upset stomach
  • numbness/increased sensitivity
  • fast heartbeat

The most common side effects in patients with PAH due to unidentified or hereditary factors with at least 10% difference between the group that received epoprostenol and the group that received conventional therapy alone were:

  • flu-like symptoms
  • fast heartbeat
  • flushing
  • diarrhea
  • nausea/vomiting
  • jaw pain
  • pain in the muscles and/or ligaments and bones
  • anxiety/nervousness
  • dizziness
  • headache
  • numbness/increased sensitivity/tingling

The most common side effects in patients with PAH due to connective tissue disease with at least 10% difference between the group that received epoprostenol and the group that received conventional therapy alone were:

  • flushing
  • low blood pressure
  • lack of appetite
  • nausea/vomiting
  • diarrhea
  • jaw pain
  • neck/joint pain
  • headache
  • skin ulcer
  • rash

Talk to your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of VELETRI®. For more information, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please read the full Prescribing Information for VELETRI®.

cp-118962

What is VELETRI® (epoprostenol) for Injection?

+

VELETRI® is a prescription medicine that is given intravenously (in a vein). It is used to treat adults with certain kinds of severe pulmonary arterial hypertension (PAH) (WHO Group 1), a condition in which blood pressure is too high in the blood vessels between the heart and the lungs. VELETRI® may improve your ability to exercise as measured by how far you can walk in 6 minutes (6-minute walk test).

Studies showing VELETRI® is effective included mainly patients with NYHA Functional Class III-IV PAH. In these patients, PAH was caused by unidentified or hereditary factors or connective tissue disease.


IMPORTANT SAFETY INFORMATION

+

Who should not take VELETRI®?

VELETRI® should not be used if you have heart failure due to severe left heart disease, if you develop fluid in the lungs (pulmonary edema) when starting therapy, or if you are allergic to epoprostenol.

Some medications may interact with VELETRI®. Please talk to your doctor about all of your medications.

What is the most important information I should know about VELETRI®?

It is important to use VELETRI® as directed by your doctor. VELETRI® should be used only with Sterile Water for Injection, USP, or Sodium Chloride 0.9% Injection, USP. Do not mix VELETRI® with other intravenous medications. Each vial is for single use only; discard any unused medication. Use at room temperature (77°F/25°C). Do not expose VELETRI® to direct sunlight.

When you take epoprostenol for the first time, you must be in a setting (hospital or clinic) where you can be monitored for any serious side effects or in case of emergency. Your blood pressure and heart rate should also be monitored with any dose changes. If you are taking VELETRI®, your doctor may prescribe another kind of medicine used to prevent blood clots. It is the use of these medications concomitantly (in combination) with VELETRI® that may potentially cause an increase in the risk of bleeding.

Sudden and dramatic changes in dose may lead to unstable blood pressure, a return of pulmonary hypertension symptoms, or fatal low blood pressure (hypotension). Do not stop using VELETRI® without first talking to your doctor.

To reduce the risk of infection in the bloodstream, it is important to know how to properly care for the catheter and infusion pump.

What are the possible side effects of VELETRI®?

You may have side effects at the start of treatment or with dose increases. The most common side effects seen in at least 1% of patients were:

  • flushing
  • headache
  • nausea/vomiting
  • low blood pressure
  • anxiety/nervousness
  • chest pain
  • dizziness
  • slow heartbeat
  • abdominal pain
  • pain in the muscles and/or ligaments and bones
  • shortness of breath
  • back pain
  • sweating
  • upset stomach
  • numbness/increased sensitivity
  • fast heartbeat

The most common side effects in patients with PAH due to unidentified or hereditary factors with at least 10% difference between the group that received epoprostenol and the group that received conventional therapy alone were:

  • flu-like symptoms
  • fast heartbeat
  • flushing
  • diarrhea
  • nausea/vomiting
  • jaw pain
  • pain in the muscles and/or ligaments and bones
  • anxiety/nervousness
  • dizziness
  • headache
  • numbness/increased sensitivity/tingling

The most common side effects in patients with PAH due to connective tissue disease with at least 10% difference between the group that received epoprostenol and the group that received conventional therapy alone were:

  • flushing
  • low blood pressure
  • lack of appetite
  • nausea/vomiting
  • diarrhea
  • jaw pain
  • neck/joint pain
  • headache
  • skin ulcer
  • rash

Talk to your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of VELETRI®. For more information, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please read the full Prescribing Information for VELETRI®.

cp-118962